Ipsen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for IPSEN, and what generic alternatives to IPSEN drugs are available?
IPSEN has four approved drugs.
There are thirty-four US patents protecting IPSEN drugs.
There are two hundred and seventy-five patent family members on IPSEN drugs in forty-six countries and twenty-six supplementary protection certificates in fifteen countries.
Drugs and US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | 11,802,115 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-002 | Jul 20, 2021 | RX | Yes | No | 9,694,018 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-001 | Aug 16, 2023 | RX | Yes | No | 9,314,439 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | SOHONOS | palovarotene | CAPSULE;ORAL | 215559-005 | Aug 16, 2023 | RX | Yes | Yes | 11,622,959 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | RX | Yes | No | 11,583,539 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Ipsen | ONIVYDE | irinotecan hydrochloride | INJECTABLE, LIPOSOMAL;INTRAVENOUS | 207793-001 | Oct 22, 2015 | RX | Yes | Yes | 9,364,473 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ipsen
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-002 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-001 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-001 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen Pharma | SOMATULINE DEPOT | lanreotide acetate | SOLUTION;SUBCUTANEOUS | 022074-003 | Aug 30, 2007 | 5,595,760 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE;ORAL | 215498-004 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
Ipsen | BYLVAY | odevixibat | CAPSULE, PELLETS;ORAL | 215498-003 | Jul 20, 2021 | 7,132,416 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ipsen Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Brazil | 112018002941 | ⤷ Try a Trial |
Denmark | 2637668 | ⤷ Try a Trial |
Russian Federation | 2574926 | ⤷ Try a Trial |
China | 109562099 | ⤷ Try a Trial |
Lithuania | 3400944 | ⤷ Try a Trial |
Australia | 2013202947 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ipsen Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3400944 | CA 2022 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719 |
3400944 | SPC/GB21/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: ODEVIXIBAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING ODEVIXIBAT SESQUIHYDRATE; REGISTERED: UK EU/1/21/1566(NI) 20210719; UK PLGB 36216/0001 20210719; UK PLGB 36216/0002 20210719 |
1746976 | SPC/GB17/043 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT; REGISTERED: UK EU/1/16/1130 20161018 |
1746976 | 132017000076571 | Italy | ⤷ Try a Trial | PRODUCT NAME: SALE SUCROSOFATO DI IRINOTECAN, COME IL SALE SUCROSOFATO DI IRINOTECAN IN UN LIPOSOMA PEGILATO(ONIVYDE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1130, 20161018 |
1746976 | C01746976/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: IRINOTECAN SUCROSOFAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65994 25.07.2017 |
1746976 | 17C1027 | France | ⤷ Try a Trial | PRODUCT NAME: SEL DE SUCROSOFATE D'IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.